Lv0
0 积分 2024-04-23 加入
Interstitial lung diseases
8天前
已完结
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease]
8天前
已完结
Pharmacodynamic Modeling of CDK4/6 Inhibition‐Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression‐Free Survival in Patients With Advanced Breast Cancer
2个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
3个月前
已完结
Targeting DNA damage response pathways in cancer
4个月前
已完结
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer
4个月前
已完结
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
6个月前
已完结
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
7个月前
已完结
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
7个月前
已完结
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma
8个月前
已完结
皖公网安备34019202002308
